LADS: a powerful vaccine platform for cancer immunotherapy and prevention
Our findings demonstrate that LADS-based vaccines represent a more powerful platform for the development of immunotherapeutic and preventive vaccines against cancers and infectious diseases.
Authors
- Jing Xia (ORCID: https://orcid.org/0000-0002-9243-9082)
- Yue Han (ORCID: https://orcid.org/0000-0002-0645-0657)
- Houhui Song (ORCID: https://orcid.org/0000-0001-6530-5794)
- Mianmian Chen (ORCID: https://orcid.org/0000-0001-8096-5651)
- Jing Sun (ORCID: https://orcid.org/0000-0002-3400-1920)
- Changyong Cheng (ORCID: https://orcid.org/0000-0002-7530-5605)
- Jiali Xu (ORCID: https://orcid.org/0000-0001-7047-7240)
- Jing Wang (ORCID: https://orcid.org/0000-0001-6882-7520)
- Xin Jiang (ORCID: https://orcid.org/0009-0004-7950-3897)
- Simin Deng (ORCID: https://orcid.org/0009-0000-0663-7078)
Institutions
- Zhejiang A & F University (CN)
Publication Details
- Journal
- BMC Biology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s12915-024-02086-7
- Citations
- 3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province